GSK CEO Emma Walmsley Files Initial Shareholding Notification
Ticker: GLAXF · Form: 6-K · Filed: Oct 11, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | low |
| Pages | 9 |
| Reading Time | 11 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, executive-disclosure
Related Tickers: GSK
TL;DR
GSK CEO Walmsley filed initial shareholding docs. Nothing major yet.
AI Summary
On October 11, 2024, GSK plc filed a Form 6-K reporting a transaction notification from Emma Walmsley, the Chief Executive Officer. This filing is an initial notification regarding her shareholding.
Why It Matters
This filing provides transparency into the shareholding of a key executive, which can be an indicator of management's confidence in the company's future performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of executive shareholding and does not indicate any immediate financial or operational risks for the company.
Key Players & Entities
- GSK plc (company) — Registrant
- Emma Walmsley (person) — Chief Executive Officer
- October 11, 2024 (date) — Filing date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Who is the subject of the transaction notification?
The transaction notification is regarding Emma Walmsley, the Chief Executive Officer of GSK plc.
What is the nature of the notification from Emma Walmsley?
It is an initial notification regarding her shareholding.
When was this filing made?
The filing was made on October 11, 2024.
What is the principal executive office address of GSK plc?
The principal executive office address is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 2,678 words · 11 min read · ~9 pages · Grade level 19.3 · Accepted 2024-10-11 11:56:34
Filing Documents
- a9370h.htm (6-K) — 278KB
- 0001654954-24-012893.txt ( ) — 279KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: October 11, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc